What Hemoclear does

HemoClear B.V. is a Dutch medical device company headquartered in Zwolle, Netherlands, that develops and commercializes an autologous blood transfusion system for surgical, trauma, obstetric, and global health applications. The company serves hospital surgical departments (cardiac, vascular, orthopedic, spine, neurosurgery, transplantation, obstetrics), military and emergency medical services, and healthcare programs in low-resource settings where donor blood is scarce or unavailable. The company's stated mission is to address complications, high costs, and supply shortages associated with allogeneic donor blood transfusion by enabling use of a patient's own shed blood.

The company's core product is a first-in-class, gravity-driven micro-filtration blood filter that uses medical-grade polyurethane film — bombarded with argon ions in a vacuum — to capture red blood cells and platelets from patient shed blood while filtering out plasma toxins, harmful agents, and activated factors. Unlike centrifugal cell savers, the device requires no electricity, centrifuge, or specialized equipment, can be operated by any healthcare professional, and produces up to 8 units of platelet-rich autologous transfusion blood in 4 hours (procedure time ~30 minutes, set-up 3–5 minutes). The filter received CE Mark approval in March 2021 and is manufactured under ISO 13485:2016; production has been centralized in the Netherlands and scaled through a partnership with VDL: Dutch PPE Solutions in Heerlen.

HemoClear generates revenue primarily through B2B hardware sales of single-use filter kits (HC01K), blood collection reservoirs, and accessories, sold to hospitals via direct enterprise field sales and exclusive territory distributors. Go-to-market combines direct hospital engagement, channel partners (Pennine Healthcare for UK/Ireland, Medista for Czech Republic), conference-driven outreach to anesthesiologists and surgeons, and grant-funded global health partnerships (e.g., Nigeria NBSA, South Africa rural programs). Pricing is quote-based and not publicly disclosed; published evidence cites up to $422 per-case cost savings, 18–33% reductions in allogeneic transfusion rates in spine surgery, and 40%/37% reductions in cardiac and open aortic surgery.

Name

Hemoclear

Legal name

HemoClear B.V.

Website

https://hemoclear.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

HemoClear B.V. is a Dutch medical device company that develops a gravity-driven micro-filtration blood filter enabling autologous blood transfusion for hospital surgical, trauma, obstetric, and low-resource healthcare settings.

Ownership category

akta.pro rank

Product category

Autologous Blood Transfusion Devices

NAICS

Blood and Organ Banks (621991)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

akta.pro secondary industry

Infusion Pumps (Ambulatory/Stationary) (HLAHAIAF)

Keywords

• Autologous blood transfusion
• Cell salvage devices
• Medical device manufacturing
• Patient blood management
• Micro-filtration blood filters

Headquarters

HQ city

Zwolle

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. HemoClear Filter Kits: Sale of medical device filter kits comprising all necessary components for cell salvage procedures. Product catalog includes HC01K – 10 Filter kits and blood collection reservoirs. Single-use device sold to hospitals and healthcare facilities.
2. Accessories and Consumables: Related accessories and consumables for the HemoClear blood system including blood collection reservoirs with connection tubes, thorax drainage sets, and post-op collection drains.
3. Manufacturing Partnership with VDL: Partnership with VDL: Dutch PPE Solutions for manufacturing the HemoClear autologous blood filter, adding to their healthcare portfolio while HemoClear focuses on innovation and commercialization.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Core offering

HemoClear develops and manufactures a gravity-driven micro-filtration autologous blood transfusion system. Its core product, the HemoClear Autologous Blood Filter, captures red blood cells and platelets from patient shed blood while filtering out plasma, toxins, and harmful agents, producing high-quality platelet-rich transfusion blood in approximately 30 minutes. The company sells filter kits, blood collection reservoirs, and accessories to hospitals, surgical departments, and global health programs.

Product overview

HemoClear offers a micro-filtration based autologous blood transfusion system centered around the HemoClear Autologous Blood Filter. The core product is a gravity-driven bedside filtration device that washes and filters patient shed blood to capture red blood cells and platelets, producing high-quality platelet-rich transfusion blood in approximately 30 minutes. The product portfolio includes the main HemoClear filter, HC01K Filter Kits (packages of 10 filters), Blood Collection Reservoirs with connection tubes, and an Accessories Kit developed with Pennine Healthcare. The system enables any healthcare professional to perform cell salvage without electricity, centrifuges, or expensive equipment, generating up to 8 units of autologous transfusion blood in 4 hours.

Differentiator

Problem solved

Functional benefit

Products and services

• HemoClear Autologous Blood Filter A gravity-driven micro-filtration blood filter that captures red blood cells and platelets from patient shed blood, separating them from plasma, toxins, and pathological elements for autologous transfusion. Device set-up takes 3-5 minutes, with the complete procedure taking approximately 30 minutes and generating up to 8 units of high-quality autologous transfusion blood in 4 hours. Designed for hospital surgical departments, obstetric care, and military/emergency settings.
• HC01K Filter Kit
• Blood Collection Reservoir with Connection Tube Blood collection reservoir with connection tube (product code C0000002) for collecting patient shed blood during or after surgery, designed as a compatible accessory to the HemoClear filter system, including thorax drainage sets and post-op collection drains.
• HemoClear Accessories Kit Complete ready-to-use accessories kit developed with Pennine Healthcare, containing all material needed to recuperate red blood cells from patient shed blood for autologous transfusion, manufactured by Pennine Healthcare as exclusive UK and Ireland distributor.

Quantifiable outcome

• 78% reduction in ICU mortality for COVID-19 patients treated with HemoClear-obtained convalescent plasma
• +7 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• LivaNova: LivaNova's Sorin Group legacy includes the XTRA and Electa autologous cell-salvage consoles, which compete directly with HemoClear in cardiac and major surgery settings.
• Brightwake: Brightwake produces autologous blood filtration devices (e.g., Hemafuse) for surgical cell salvage in low-resource settings, making it one of the closest direct peers to HemoClear's gravity-driven filter concept.
• Haemonetics: Haemonetics' Cell Saver system is the dominant centrifugal autologous blood cell-salvage device used in operating rooms globally, competing head-to-head with HemoClear's micro-filtration filter in surgical departments.

Emerging players

• CytoSorbents: CytoSorbents' CytoSorb blood-purification technology operates in adjacent intraoperative and ICU blood-filtration applications, partially overlapping with HemoClear's positioning in surgical and critical-care blood management.
• Velico Medical: Velico Medical focuses on front-line blood product processing and storage technologies for transfusion medicine, addressing a similar end-customer (blood banks and surgical teams) as HemoClear.
• i-SEP: i-SEP is a French medtech developing an innovative autologous whole-blood filtration system for surgical and trauma settings, overlapping directly with HemoClear's filtration approach and target use cases.

Broad incumbents

• Fresenius Kabi: Fresenius Kabi offers a broad portfolio of blood collection, processing, and transfusion devices (including CompoFlow and related consumables), positioning it as a broad incumbent across the transfusion-medicine supply chain that overlaps with HemoClear.
• Medtronic (Perfusion/Cell Saver legacy): Medtronic's historical perfusion and cell-saver franchises (e.g., the autolog system) compete in the same surgical cell-salvage category as HemoClear, although Medtronic has a much broader device portfolio.
• Terumo BCT: Terumo BCT provides Spectra Optia and other apheresis/cell-processing systems used in operating rooms and blood banks, serving as a broad incumbent in cell salvage and blood component processing.

Others

• Pennine Healthcare: Pennine Healthcare is HemoClear's exclusive UK/Ireland distributor and co-developer of the HemoClear Accessories Kit, making it a partner rather than competitor but highly relevant as a channel comparison for autologous blood device go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hemoclear-b-v
• Xx.com/HemoClear
• Facebookfacebook.com/profile.php

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hemoclear